A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 83
- Population
- ALL · 30 Years to 75 Years
- Duration
- 2025-09-16 to 2026-12-30
- Intervention
- Fisetin intervention; Placebo; Urolithin A intervention
- Comparator
- Placebo Control group
- Outcomes measured
- Subjective Sleep Quality Score — From enrollment to the end of intervention at 12 weeks; Chronotype — From enrollment to the end of intervention at 12 weeks; Polysomnography — From enrollment to the end of intervention at 12 weeks; Number of participants with abnormal blood and urine routine tests results — From enrollment to the end of intervention…; Homeostatic Model Assessment of Insulin Resistance — From enrollment to the end of intervention at 12 weeks; Frailty Assessment — From enrollment to the end of intervention at 12 weeks; Fatigue Severity Scale Score — From enrollment to the end of intervention at 12 weeks; Patient Health Questionnaire-9 Score — From enrollment to the end of intervention at 12 weeks; Generalized Anxiety Disorder Scale Score — From enrollment to the end of intervention at 12 weeks; Determination of Plasma Immunoglobulin Levels (g/L) — From enrollment to the end of intervention at 12 weeks; DNA Methylation Clock — From enrollment to the end of intervention at 12 weeks; Profile of Mood States-Short Form (Chinese Version) Score — From enrollment to the end of intervention at 12 weeks; Plasma Interleukin Levels — From enrollment to the end of intervention at 12 weeks; Gut Microbiota Diversity Analysis (Based on 16S rRNA Gene Sequencing) — From enrollment to the end of intervention at 1…; D-lactic acid level — From enrollment to the end of intervention at 12 weeks; NAD+ Level Measurement — From enrollment to the end of intervention at 12 weeks; Quality of Life Assessment — From enrollment to the end of intervention at 12 weeks; Arterial stiffness assessment — From enrollment to the end of intervention at 12 weeks; Cardiopulmonary exercise testing — From enrollment to the end of intervention at 12 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Biological age biomarkers · 100%Title contains controlled term: aging biomarker. Abstract contains controlled term: aging biomarker. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
- Sleep · 100%Title contains controlled term: sleep. Abstract contains controlled term: sleep. Source terminology contains: sleep. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
- Urolithin A · 100%Title contains controlled term: urolithin a. Abstract contains controlled term: urolithin a. Source terminology contains: urolithin a. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.